Recipharm and Laccure agree commercial collaboration
Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary.
Press Releases
Oncorena strengthens its Board
Oncorena Holding AB today announces that the company at an extra shareholder’s meeting decided to strengthen the board following the capitalization earlier this autumn.
Oncorena secures MSEK 24 for clinical studies of metastasized kidney cancer
Oncorena Holding AB today announces that the company through a new share issue has secured capital to conduct clinical studies of a completely new treatment principle for kidney cancer.
Successful new share issue in AcuCort
During August and September AcuCort AB implemented a preferential new share issue amounting to MSEK 6, which was over-subscribed. The share issue was implemented in order to provide capital for the operations and to broaden the ownership in preparation for a planned listing in 2017.
Adenovir Pharma brings in MSEK 5.5 in preparation for the exit process
Adenovir Pharma is pleased to announce that the company has performed a new share issue totaling MSEK 5.5 and that the company has started its exit process. The company develops a pharmaceutical…
Glactone Pharma to participate at ACCR Annual Meeting 2016, April 16-20, in New Orleans, USA
Glactone Pharma will participate at the American Association of Cancer Research (ACCR) Annual meeting which is one of the largest and most important events in the world for researchers in the…
Glactone Pharma’s preferential rights issue fully subscribed
Glactone Pharma is pleased to announce that the company’s recent preferential rights issue was fully subscribed. The capital injection will be used for further development of the company’s unique…
Adenovir Pharma strengthens its patents for treatment of the serious and very contagious eye infection EKC
Adenovir Pharma´s patent applications relating to its novel “antiviral compound” (APD-209) for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC),…
Glactone Pharma announces appointments to new Scientific Advisory Board
Glactone Pharma is pleased to announce the appointment of leading experts to its newly formed Scientific Advisory Board. The board will provide guidance and expertise that further strengthens the company’s research and development portfolio.
New publication concerning EKC − a very contagious eye infection caused by adenoviruses
A Swedish research group has published scientific discoveries concerning the serious infectious eye disease EKC (epidemic keratoconjunctivitis) in the prestigious journal Acta Ophthalmologica.The researchers have shown that patients exhibit more severe symptoms and clinical findings in EKC caused by some specific adenoviruses.
Glactone Pharma to present at Biotech Showcase™ 2016, on January 13, in San Francisco, USA
Martin Johansson, CEO of Glactone Pharma AB, to present at Biotech Showcase™. “Investors and biopharmaceutical executives from around the world gather in San Francisco during this week and…